Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Liposomal Encapsulation Of Azidothymidine Results In Decreased Hematopoietic Toxicity And Enhanced Activity Against Murine Acquired Immunodeficiency Syndrome.

N. Phillips, C. Tsoukas
Published 1992 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
This study has determined the effect of liposomal encapsulation on the hematopoietic toxicity and antiviral activity of 3'-azido-3'-deoxythymidine (AZT) in mice. Daily intravenous administration in the dose range 0.4 to 10 mg/kg body weight for 5 days significantly depressed bone marrow cellularity with a corresponding decrease in red blood cell, blood neutrophil, and monocyte numbers. Maximum toxicity was seen at 2 mg/kg or greater. Liposomal encapsulation of AZT and administration at 2 mg/kg abrogated the toxicity of AZT. The neutrophil inflammatory response to thioglycollate injected intraperitoneally was significantly inhibited by AZT at all doses, whereas liposomal AZT was without effect. The inhibitory activity of AZT against Concanavalin A (Con A)-stimulated splenic lymphocyte proliferation in vitro was reduced on liposomal encapsulation of AZT, while treatment of mice with liposomal AZT but not free AZT resulted in a significant reduction of Con A-stimulated proliferation. Liposomal AZT was more effective than AZT in preventing the development of plasma reverse transcriptase activity and the depletion of Thy 1.2(+)-L3T4+ T cells after infection of mice with LP-BM5 retrovirus. These results indicate that AZT-induced hematopoietic toxicity may not be a limiting factor for antiviral therapy, and that the use of liposomes to deliver AZT results in enhanced antiretroviral activity in mice.
This paper references
10.1128/AAC.35.2.322
Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells.
R. Dornsife (1991)
10.1016/0020-7292(89)90638-3
Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection
PA Pizzo (1988)
The liposome-mediated macrophage suicide technique
N. Vanrooijen (1989)
10.1002/AJH.2830300416
Reversible agranulocytosis related to azidothymidine therapy
J. Goldsmith (1989)
10.1128/JVI.63.3.1223-1231.1989
Retrovirus-induced murine acquired immunodeficiency syndrome: natural history of infection and differing susceptibility of inbred mouse strains.
J. Hartley (1989)
Nussinoff-Lehrman S: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex
DD Richman (1987)
10.1038/323467A0
Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidine
R. Ruprecht (1986)
10.1093/OXFORDJOURNALS.QJMED.A068309
The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study.
D. Stambuk (1989)
Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.
N. Phillips (1987)
10.1001/JAMA.1989.03420060069034
Cessation of zidovudine therapy may lead to increased replication of HIV-1.
M. Wainberg (1989)
Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer.
G. López-Berestein (1984)
The liposome-mediated macrophage 'suicide' technique.
N. van Rooijen (1989)
10.1097/00002030-198909000-00001
Nature, time course and dose dependence of zidovudine‐related side effects: results from the Multicenter Canadian Azidothymidine Trial
K. Gelmon (1989)
Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes.
A. Rahman (1985)
Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative.
N. Phillips (1985)
10.1089/AID.1990.6.929
Reversal of azidothymidine-induced bone marrow suppression by 2',3'-dideoxythymidine as studied by hemopoietic clonal culture.
Y. Yoshida (1990)
10.1073/PNAS.83.21.8333
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.
P. Furman (1986)
10.1016/S0140-6736(88)92903-0
EFFECTS OF ZIDOVUDINE IN 365 CONSECUTIVE PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX
E. Dournon (1988)
A selective signaling defect in helper T cells induced by antigen-presenting cells from mice with murine acquired immunodeficiency syndrome.
T. Mizuochi (1990)
Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously.
I. Fidler (1985)
Zidovudine (azido dideoxythymidine) inhibits characteristic early alterations of lymphoid cell populations in retrovirus-induced murine AIDS.
D. Portnoi (1990)
Abrogation of resistance to severe smallpox in C57BL/6 mice infected with LP-BM5 virus
RML Buller (1987)
10.1111/j.1365-2141.1991.tb07968.x
Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice
F. P. Chow (1991)
10.1128/AAC.34.4.605
3'-Azido-3'-deoxythymidine prevents induction of murine acquired immunodeficiency syndrome in C57BL/10 mice infected with LP-BM5 murine leukemia viruses, a possible animal model for antiretroviral drug screening.
H. Ohnota (1990)
Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation.
E. Herman (1983)
Liposome-encapsulated doxorubicin. Preliminary results of phase-I and phase-I1 trials, in Lopez-Berestein G, Fidler IJ: (eds): Liposomes in the Therapy of Infectious Diseases and Cancer
J Treat (1989)
10.7326/0003-4819-107-4-502
Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS).
P. Gill (1987)
10.1200/JCO.1987.5.2.310
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
G. López-Berestein (1987)
10.1002/EJI.1830201237
A unique subset of normal murine CD4+ T cells lacking Thy‐1 is expanded in a murine retrovirus‐induced immunodeficiency syndrome, MAIDS
K. Holmes (1990)
10.1128/AAC.31.12.1901
Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections.
R. Mehta (1987)
The efficacy of azidothymidine ( U T ) in the treatment of patients with AIDS and AIDSrelated complex. A double-blind, placebo-controlled trial
S Segreti (1987)
10.1038/2261209A0
Viral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of RNA Tumour Viruses
D. Baltimore (1970)
10.1084/JEM.161.4.766
Retroviral induction of acute lymphoproliferative disease and profound immunosuppression in adult C57BL/6 mice
D. E. Mosier (1985)
10.1016/0923-2516(90)90018-E
The spleen in HIV infection--morphological evidence of HIV-associated macrophage dysfunction.
S. Falk (1990)
PS: Pharmacological, toxicological and therapeutic evaluation of doxorubicin entrapped in cardiolipin liposomes
A Rahman (1985)
Morse HC 111: Contribution of helper T cells to the pathogenesis of murine AIDS
De Mosier
10.1007/BF02421330
Susceptibility to a mouse acquired immunodeficiency syndrome is influenced by theH-2
Diane Hamelin-Bourassa (2006)
10.1016/S0140-6736(86)92808-4
ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX
R. Yarchoan (1986)
10.1002/AJH.2830350102
Role of heme metabolism in AZT‐induced bone marrow toxicity
J. Lutton (1990)
10.1056/NEJM198707233170401
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
M. Fischl (1987)
10.1146/ANNUREV.IY.08.040190.001125
Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection.
M. S. Meltzer (1990)
Immunoliposome targeting to CD4+ cells in human blood.
N. Phillips (1990)
10.1089/AID.1990.6.691
Inhibition of HIV-1 in monocyte/macrophage cultures by 2',3'-dideoxycytidine-5'-triphosphate, free and in liposomes.
J. Szebeni (1990)
10.1073/PNAS.87.10.3933
Human immunodeficiency virus causes mononuclear phagocyte dysfunction.
G. Baldwin (1990)
10.7326/0003-4819-108-2-175
Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT).
G. G. Jackson (1988)
10.1016/S0140-6736(74)90682-5
Drug-carrier potential of liposomes in cancer chemotherapy.
G. Gregoriadis (1974)
10.1056/nejm198707233170402
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
D. Richman (1987)
Contribution of helper T cells to the pathogenesis of murine AIDS
DE Mosier (1988)
Characteristics of B cell proliferation and activation in murine AIDS.
D. Klinman (1989)
10.1093/INFDIS/161.5.1006
Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model.
T. Basham (1990)
10.1016/S0006-291X(88)81026-X
Azidothymidine inhibits mitogen stimulated growth and DNA-repair in human peripheral lymphocytes.
B. Munch-Petersen (1988)



This paper is referenced by
LIPOSOMAL DRUG DELIVERY SYSTEM FOR ZIDOVUDINE: DESIGN ANDCHARACTERIZATION
Bhambere Deepak Sunil (2010)
10.3390/v4040488
Nanotechnology and the Treatment of HIV Infection
R. Parboosing (2012)
10.1002/wnan.118
Nanotechnology and HIV: potential applications for treatment and prevention.
P. Kim (2010)
10.15744/2454-499X.2.103
An Introduction to the Approaches of Novel Drug Delivery Systems for Acquired Immune Deficiency Syndrome (AIDS)
N. Singh (2016)
10.1234/JGPT.V1I1.34
FORMULATION AND CHARACTERIZATION OF VESICULAR DRUG DELIVERY SYSTEM FOR ANTI-HIV DRUG
R. Doijad (2009)
10.5772/20834
Exploring the Nanotechnology-Based Drug Delivery Systems for AIDS Treatment
F. Carvalho (2011)
Formation de liposomes par un procédé innovant utilisant les fluides supercritiques
L. Lesoin (2011)
10.1016/j.taap.2009.01.027
Liposomal formulation of alpha-tocopheryl maleamide: in vitro and in vivo toxicological profile and anticancer effect against spontaneous breast carcinomas in mice.
J. Turánek (2009)
10.2147/IJN.S8905
Magnetic nanoformulation of azidothymidine 5’-triphosphate for targeted delivery across the blood–brain barrier
Z. Saiyed (2010)
10.1016/j.ejps.2018.06.017
Optimization of nanostructured lipid carriers for Zidovudine delivery using a microwave‐assisted production method
S. M. Cavalcanti (2018)
Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid.
J. Drach (1993)
10.1080/10611860802475688
Lymphatic targeting of zidovudine using surface-engineered liposomes
C. D. Kaur (2008)
10.1007/978-1-4614-0554-2
Long Acting Injections and Implants
J. Wright (2012)
DESENVOLVIMENTO DE NANOPARTÍCULAS DE PLA E PLA-PEG PARA ADMINISTRAÇÃO INTRANASAL DE ZIDOVUDINA
R. Mainardes (2007)
10.1155/2014/854018
Pharmacokinetic and Tissue Distribution Study of Solid Lipid Nanoparticles of Zidovudine in Rats
Shah Purvin (2014)
10.3109/10611869808997877
Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection.
A. Désormeaux (1998)
10.1128/AAC.45.9.2623-2627.2001
Treatment of Visceral Leishmaniasis with Sterically Stabilized Liposomes Containing Camptothecin
M. Proulx (2001)
Nanotecnología y microbicidas: protección frente a la infección por VIH
J. S. Rodríguez (2012)
10.2147/IJN.S7681
Progress in antiretroviral drug delivery using nanotechnology
R. Mallipeddi (2010)
Retinoic Acid trans Acute Promyelocytic Leukemia Cells by Liposomal All-Induction of Differentiation in Myeloid Leukemia Cell Lines and Updated
Johannes (2006)
10.1517/17425247.3.5.613
Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites
Tushar K Vyas (2006)
10.1016/j.ejpb.2008.06.020
Exploring the use of novel drug delivery systems for antiretroviral drugs.
E. Ojewole (2008)
10.5772/60961
Novel Prospective Treatment Options
J. Stanley (2015)
10.1517/17425247.2015.1042857
Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics
M. Dobrovolskaia (2015)
10.1023/A:1011050209986
Targeting of 3′-Azido 3′-Deoxythymidine (AZT)-Loaded Poly(Isohexylcyanoacrylate) Nanospheres to the Gastrointestinal Mucosa and Associated Lymphoid Tissues
Assia Dembri (2004)
10.3390/nano10091645
Antiviral Potential of Nanoparticles—Can Nanoparticles Fight Against Coronaviruses?
S. Gurunathan (2020)
10.1128/AAC.40.6.1467
Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro.
A. Bender (1996)
10.18452/17013
HIV-1: identification of a pathway for virus release and development of a new nanotechnological strategy to counteract the infection
Andrea Gramatica (2014)
The effect of Nanoliposomal and PE Gylated Nanoliposomal Forms of 6- Gingerol on Breast Cancer Cells
M. Khalili (2013)
10.1016/j.addr.2009.11.017
Nanotechnology-based systems for the treatment and prevention of HIV/AIDS.
J. das Neves (2010)
Semantic Scholar Logo Some data provided by SemanticScholar